Your session is about to expire
← Back to Search
Nemvaleukin Alfa + Pembrolizumab for Cancer (ARTISTRY-3 Trial)
ARTISTRY-3 Trial Summary
This trial will have 2 groups of people who will be studied. One group will be studied at one center and the other group will be studied at multiple centers.
ARTISTRY-3 Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowARTISTRY-3 Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2024 Phase 2 trial • 57 Patients • NCT03004183ARTISTRY-3 Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have never received IL-2 or IL-15 protein therapy.I am a woman who can have children and my pregnancy test is negative.I have active brain metastases.My blood counts are within a healthy range.I have had another type of cancer within the last 2 years.My liver and kidneys are working well.My last cancer treatment was over 4 weeks ago, and my biopsy was done within the last 3 months.I waited at least 4 weeks after my last anti-PD-1 therapy before getting a screening biopsy.I've had 1-3 prior treatments for my condition, including any before or after surgery.I haven't taken any immune system affecting drugs in the last 4 weeks or 5 half-lives.I've had immunotherapy without severe side effects or had to stop due to them.I have a history of HIV or hepatitis B/C or currently test positive for them.I have a confirmed diagnosis of a specific advanced cancer type and at least one tumor that can be biopsied.I have a specific type of cancer and treatments have not worked or caused intolerance.I take more than 10 mg of prednisone daily or its equivalent.I have not had radiotherapy in the last 4 weeks.
- Group 1: Cohort 2 Part B: Less Frequent IV Dosing Nemvaleukin and Pembrolizumab
- Group 2: Cohort 1: Tumor Microenvironment (TME) Nemvaleukin and Pembrolizumab
- Group 3: Cohort 2 Part A: Less Frequent IV Dosing Nemvaleukin
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
In which areas are the trials of this clinical research taking place?
"This research initiative is ongoing in 4 different healthcare facilities, which are situated in Houston, West Valley City and Grand Rapids. To reduce travel costs for participants, it's vital to choose the site nearest you."
What is the current patient count for this clinical trial?
"Affirmative. The clinical trial is currently seeking enrollees, with the original list published on September 30th 2020 and last updated August 30th 2022. In total, 78 participants will be recruited from 4 different locales."
Are there any opportunities presently available to participate in this research?
"Affirmative, according to clinicaltrials.gov this research is currently recruiting participants. Initially posted on September 30th 2020 and edited most recently on August 30th 2022, the trial aims to include 78 patients from 4 distinct health facilities."
For which medical conditions is the prescription Pembrolizumab typically prescribed?
"Pembrolizumab is used to combat cancerous growths, including unresectable melanoma and microsatellite instability high. It has also been shown effective for patients with chemotherapy-resistant disease progression."
Has Pembrolizumab been trialed in the past for any medical purposes?
"Initially studied at City of Hope, pembrolizumab has been researched in a total of 251 trials. At present, 961 studies are underway with numerous of these investigations being conducted in Houston, Texas."
Share this study with friends
Copy Link
Messenger